This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Robbins Umeda LLP Announces An Investigation Of The Acquisition Of Trubion Pharmaceuticals, Inc. By Emergent Biosolutions Inc.

Robbins Umeda LLP has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by members of the Board of Directors of Trubion Pharmaceuticals, Inc. ("Trubion" or the "Company") (NASDAQ: TRBN) in connection with their efforts to sell Trubion to Emergent Biosolutions Inc. ("Emergent") (NYSE: EBS). If the transaction is completed, Trubion shareholders will receive $1.365 in cash and 0.1641 shares of Emergent common stock for each share of Trubion they hold, for an implied value of approximately $4.40 per share. Trubion shareholders will also receive one Contingent Value Right per share, which will entitle the holder to receive cash payments based upon achievement of predefined milestones. The transaction is expected to close in the fourth quarter of 2010.

Robbins Umeda LLP's investigation concerns whether the Board of Directors of Trubion undertook a fair process to obtain fair consideration for all shareholders of Trubion. Specifically, our investigation concerns whether the Company's Board of Directors breached their fiduciary duties to Trubion shareholders by failing to adequately shop the Company before entering into the transaction with Emergent. Notably, at least one analyst has set a price target for Trubion of $7.00 per share, $2.60 higher than the implied value of Emergent's offer. Additionally, even if Emergent hits all the predefined milestones, the consideration is still below the analyst target.

If you are a shareholder of Trubion, plan to continue to hold your shares, and would like more information about your rights as a shareholder, please contact attorney Gregory E. Del Gaizo at 800-350-6003 or by e-mail at

Robbins Umeda LLP is a California-based law firm with significant experience representing investors in merger-related shareholder class actions, shareholder derivative actions, and securities fraud class actions. For more information about the firm, please go to


1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
AAPL $130.28 0.47%
FB $81.53 -1.07%
GOOG $565.06 3.30%
TSLA $218.42 -0.08%
YHOO $44.52 1.89%


DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs